Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
MCK Stock Forecast 2025-2026
$710.64
Current Price
$88.76B
Market Cap
Buy 13
Hold 3
Sell 1
Wall St Analyst Ratings
Distance to MCK Price Targets
+15.4%
To High Target of $820.00
+7.6%
To Median Target of $765.00
-14.2%
To Low Target of $610.00
MCK Price Momentum
-1.9%
1 Week Change
+2.7%
1 Month Change
+27.3%
1 Year Change
+24.7%
Year-to-Date Change
-2.8%
From 52W High of $731.00
+53.0%
From 52W Low of $464.42
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching McKesson (MCK) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on MCK and similar high-potential opportunities.
Latest MCK Stock Price Targets & Analyst Predictions
Based on our analysis of 25 Wall Street analysts, MCK has a bullish consensus with a median price target of $765.00 (ranging from $610.00 to $820.00). The overall analyst rating is Strong Buy (8.6/10). Currently trading at $710.64, the median forecast implies a 7.6% upside. This outlook is supported by 13 Buy, 3 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MCK Analyst Ratings
13
Buy
3
Hold
1
Sell
MCK Price Target Range
Low
$610.00
Average
$765.00
High
$820.00
Current: $710.64
Latest MCK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MCK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 9, 2025 | B of A Securities | Michael Cherny | Buy | Maintains | $800.00 |
| Apr 29, 2025 | UBS | Kevin Caliendo | Buy | Maintains | $805.00 |
| Apr 11, 2025 | B of A Securities | Michael Cherny | Buy | Maintains | $755.00 |
| Apr 3, 2025 | Mizuho | Steven Valiquette | Neutral | Maintains | $690.00 |
| Apr 2, 2025 | Morgan Stanley | Erin Wright | Overweight | Maintains | $745.00 |
| Mar 14, 2025 | Wells Fargo | Stephen Baxter | Equal-Weight | Maintains | $691.00 |
| Feb 6, 2025 | Evercore ISI Group | Elizabeth Anderson | Outperform | Maintains | $675.00 |
| Jan 10, 2025 | Citigroup | Daniel Grosslight | Buy | Maintains | $677.00 |
| Jan 6, 2025 | B of A Securities | Michael Cherny | Buy | Maintains | $650.00 |
| Dec 17, 2024 | Morgan Stanley | Erin Wright | Overweight | Maintains | $642.00 |
| Dec 13, 2024 | Wells Fargo | Stephen Baxter | Equal-Weight | Maintains | $641.00 |
| Nov 13, 2024 | Citigroup | Daniel Grosslight | Buy | Maintains | $713.00 |
| Nov 7, 2024 | Baird | Eric Coldwell | Outperform | Upgrade | $688.00 |
| Nov 7, 2024 | Evercore ISI Group | Elizabeth Anderson | Outperform | Maintains | $680.00 |
| Oct 7, 2024 | Leerink Partners | Michael Cherny | Outperform | Maintains | $630.00 |
| Sep 25, 2024 | Deutsche Bank | George Hill | Buy | Maintains | $579.00 |
| Sep 24, 2024 | Baird | Eric Coldwell | Neutral | Downgrade | $531.00 |
| Sep 13, 2024 | Wells Fargo | Stephen Baxter | Equal-Weight | Maintains | $535.00 |
| Sep 10, 2024 | Citigroup | Daniel Grosslight | Buy | Maintains | $630.00 |
| Sep 5, 2024 | Leerink Partners | Michael Cherny | Outperform | Maintains | $665.00 |
McKesson Corporation (MCK) Competitors
The following stocks are similar to McKesson based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
McKesson Corporation (MCK) Financial Data
McKesson Corporation has a market capitalization of $88.76B with a P/E ratio of 27.6x. The company generates $359.05B in trailing twelve-month revenue with a 0.9% profit margin.
Revenue growth is +18.9% quarter-over-quarter, while maintaining an operating margin of +1.5% and return on equity of -194.5%.
Valuation Metrics
Market Cap
$88.76B
Enterprise Value
$92.02B
P/E Ratio
27.6x
PEG Ratio
19.3x
Price/Sales
0.2x
Growth & Margins
Revenue Growth (YoY)
+18.9%
Gross Margin
+4.0%
Operating Margin
+1.5%
Net Margin
+0.9%
EPS Growth
+59.3%
Financial Health
Cash/Price Ratio
+6.4%
Current Ratio
0.9x
Debt/Equity
-4.4x
ROE
-194.5%
ROA
+4.3%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
McKesson Corporation (MCK) Business Model
About McKesson Corporation
What They Do
Healthcare services and distribution company.
Business Model
The company generates revenue primarily through wholesale drug distribution, providing healthcare IT systems, and offering pharmacy management solutions. By efficiently delivering pharmaceuticals and medical products to various healthcare facilities, McKesson ensures a steady flow of income while enhancing operational efficiencies within the healthcare sector.
Additional Information
With a significant market presence in North America, McKesson plays a crucial role in the healthcare supply chain, contributing to improved patient care and innovation in healthcare logistics. Its global operations position it as a key player in responding to the evolving demands of the medical industry.
Company Information
Sector
Healthcare
Industry
Medical Distribution
Employees
45,000
CEO
Mr. Brian S. Tyler Ph.D.
Country
United States
IPO Year
1994
Website
www.mckesson.comMcKesson Corporation (MCK) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Is McKesson (MCK) a Buy as Wall Street Analysts Look Optimistic?
Based on the average brokerage recommendation (ABR), McKesson (MCK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
May 22, 2025
By Zacks Equity Research
Fundamental Analysis
Cooper Companies Q2 Earnings Likely to Reflect Seasonal Trends
COO's fiscal second-quarter results are expected to follow seasonal trends, with a lighter start compared to the previous two reported quarters.
May 20, 2025
By Zacks Equity Research
Analyst Blog
3 Reasons Growth Investors Will Love McKesson (MCK)
McKesson (MCK) possesses solid growth attributes, which could help it handily outperform the market.
May 14, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Wall Street analysts' ratings significantly influence investors' decisions on stocks and can impact stock prices, highlighting their importance in the investment process.
Why It Matters
Wall Street analysts' ratings influence investor sentiment and stock prices, impacting trading strategies and market trends. Their recommendations can lead to significant volatility in stock valuations.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
McKesson's shares rose 4.4% after Q4 fiscal 2025 earnings, showing investor confidence. Full-year revenues reached $359 billion, with adjusted EPS up 20% to $33.05.
Why It Matters
McKesson's strong earnings growth and record revenues boost investor confidence, signaling effective strategy and positive long-term prospects, which can drive stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
McKesson's stock has shown consistent growth due to strong financials and investor support, driven by expanding oncology and biopharmaceutical sales, making it a defensive long-term investment.
Why It Matters
McKesson's strong upward stock trend, driven by solid financials and growth in high-demand sectors, signals robust long-term potential despite high valuation, indicating a defensive investment opportunity.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
A new methodology highlights selecting high-growth dividend stocks based on growth sustainability, with a final list of ten stocks chosen for sector diversity and positive momentum.
Why It Matters
The methodology highlights a focus on sustainable growth over high yields, guiding investors toward potentially resilient stocks in diverse sectors, enhancing long-term portfolio performance.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
On May 8, 2025, McKesson Corporation announced plans to spin off its Medical-Surgical Solutions segment into a new independent company, aiming to maximize shareholder value.
Why It Matters
McKesson's plan to spin off its Medical-Surgical Solutions segment may unlock shareholder value, attract investor interest, and lead to a more focused business strategy for both companies.
Source: Forbes
Market Sentiment:
Positive
Quick Summary
McKesson (MCK) is expected to exhibit strong growth potential, positioning it to potentially outperform market averages.
Why It Matters
McKesson's solid growth attributes suggest strong future performance, potentially leading to increased stock value and attracting investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About MCK Stock
What is McKesson Corporation's (MCK) stock forecast for 2025?
Based on our analysis of 25 Wall Street analysts, McKesson Corporation (MCK) has a median price target of $765.00. The highest price target is $820.00 and the lowest is $610.00.
Is MCK stock a good investment in 2025?
According to current analyst ratings, MCK has 13 Buy ratings, 3 Hold ratings, and 1 Sell ratings. The stock is currently trading at $710.64. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MCK stock?
Wall Street analysts predict MCK stock could reach $765.00 in the next 12 months. This represents a 7.6% increase from the current price of $710.64. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is McKesson Corporation's business model?
The company generates revenue primarily through wholesale drug distribution, providing healthcare IT systems, and offering pharmacy management solutions. By efficiently delivering pharmaceuticals and medical products to various healthcare facilities, McKesson ensures a steady flow of income while enhancing operational efficiencies within the healthcare sector.
What is the highest forecasted price for MCK McKesson Corporation?
The highest price target for MCK is $820.00 from at , which represents a 15.4% increase from the current price of $710.64.
What is the lowest forecasted price for MCK McKesson Corporation?
The lowest price target for MCK is $610.00 from at , which represents a -14.2% decrease from the current price of $710.64.
What is the overall MCK consensus from analysts for McKesson Corporation?
The overall analyst consensus for MCK is bullish. Out of 25 Wall Street analysts, 13 rate it as Buy, 3 as Hold, and 1 as Sell, with a median price target of $765.00.
How accurate are MCK stock price projections?
Stock price projections, including those for McKesson Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 23, 2025 4:23 AM UTC